Table 9 Current ongoing early phase I/II trials with NTRK fusion inhibitors
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
NTRK gene fusion inhibitors | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (phase) | Study design | Disease |
Larotrectinib | TRK fusion inhibitor | NCT02576431 (2) | Monotherapy | Solid tumors including NSCLC with NTRK fusions |
Repotrectinib | TRK, ROS 1, ALK fusion inhibitor | NCT03093116 (1) | Monotherapy | Solid tumor including NSLC with ALK, ROS1, NTRK1/2/3 gene rearrangement |
Entrectinib | ROS1 and TRK fusion inhibitor | NCT02568267 (2) | Monotherapy | Solid tumors including NSCLC with NTRK fusions and ROS1 rearrangements |
VMD-928 | small-molecule TrkA (NTRK1) inhibitor | NCT03556228 (1) | Monotherapy | Advanced solid tumors and lymphoma including NSCLC |